[go: up one dir, main page]

MXPA06011046A - Ciertos compuestos basados en triazol, composiciones, y usos de los mismos. - Google Patents

Ciertos compuestos basados en triazol, composiciones, y usos de los mismos.

Info

Publication number
MXPA06011046A
MXPA06011046A MXPA06011046A MXPA06011046A MXPA06011046A MX PA06011046 A MXPA06011046 A MX PA06011046A MX PA06011046 A MXPA06011046 A MX PA06011046A MX PA06011046 A MXPA06011046 A MX PA06011046A MX PA06011046 A MXPA06011046 A MX PA06011046A
Authority
MX
Mexico
Prior art keywords
compositions
based compounds
certain triazole
chemical entities
triazole
Prior art date
Application number
MXPA06011046A
Other languages
English (en)
Inventor
Carl Nicholas Hodge
John K Dickson Jr
Ioana G Popa-Burke
Jose Serafin Mendoza
Original Assignee
Amphora Discovery Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amphora Discovery Corp filed Critical Amphora Discovery Corp
Publication of MXPA06011046A publication Critical patent/MXPA06011046A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen entidades quimicas basadas en tio-triazol que exhiben una actividad inhibidora de las enzimas que utilizan ATP, metodos para utilizar estas entidades quimicas, y composiciones que comprenden tales entidades quimicas.
MXPA06011046A 2004-03-26 2005-03-25 Ciertos compuestos basados en triazol, composiciones, y usos de los mismos. MXPA06011046A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55679504P 2004-03-26 2004-03-26
US63894404P 2004-12-23 2004-12-23
PCT/US2005/010083 WO2005097758A1 (en) 2004-03-26 2005-03-25 Certain triazole-based compounds, compositions, and uses thereof

Publications (1)

Publication Number Publication Date
MXPA06011046A true MXPA06011046A (es) 2007-03-21

Family

ID=35124987

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06011046A MXPA06011046A (es) 2004-03-26 2005-03-25 Ciertos compuestos basados en triazol, composiciones, y usos de los mismos.

Country Status (8)

Country Link
US (1) US20050288347A1 (es)
EP (1) EP1730124A4 (es)
JP (1) JP2007530589A (es)
AU (1) AU2005230867A1 (es)
BR (1) BRPI0509172A (es)
CA (1) CA2560954A1 (es)
MX (1) MXPA06011046A (es)
WO (1) WO2005097758A1 (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
US7385084B2 (en) 2004-06-23 2008-06-10 Synta Pharmaceutical Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
ES2399241T3 (es) * 2004-11-18 2013-03-26 Synta Pharmaceuticals Corporation Compuestos de triazol que modulan la actividad de HSP90
JP2008536875A (ja) 2005-04-15 2008-09-11 シンタ ファーマシューティカルズ コーポレーション ビス（チオヒドラジド）アミド化合物による併用癌療法
TWI446910B (zh) 2005-08-18 2014-08-01 Synta Pharmaceuticals Corp 調節ｈｓｐ９０活性的三唑化合物
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7695911B2 (en) 2005-10-26 2010-04-13 Celera Corporation Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof
CA2653217A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
TWI490212B (zh) * 2006-05-25 2015-07-01 Synta Pharmaceuticals Corp 調節ｈｓｐ９０活性之三唑化合物
AU2007267859B2 (en) 2006-05-25 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
CA2653327A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
WO2007139952A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for the preparation of triazole compounds with hsp90 modulating activity
JP5441690B2 (ja) * 2006-05-25 2014-03-12 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
AU2007288338B2 (en) 2006-08-21 2012-05-03 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US7939564B2 (en) 2006-08-31 2011-05-10 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
WO2008051416A2 (en) * 2006-10-19 2008-05-02 Synta Pharmaceuticals Corp. Compounds that inhibit the activity of hsp90 for treating infections
CN101234113B (zh) * 2007-02-01 2011-10-26 中国人民解放军第二军医大学 一种靶向于人磷脂酰乙醇胺结合蛋白4的抗肿瘤小分子化合物
JP5523839B2 (ja) 2007-02-08 2014-06-18 シンタ ファーマシューティカルズ コーポレーション 癌などの増殖障害の治療に有用なトリアゾール化合物
US20100169038A1 (en) * 2007-04-23 2010-07-01 Tufts University Methods for calculating particle size distribution
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
KR100980328B1 (ko) * 2007-12-14 2010-09-06 한국생명공학연구원 단백질 포스파타제의 활성을 억제하는트리아졸릴-티오-에타논 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 암 예방 및 치료용조성물
MX2010011258A (es) * 2008-04-14 2011-06-20 Univ Texas Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
EP2172209A1 (en) * 2008-10-03 2010-04-07 Universite Pierre Et Marie Curie Treatment of mood and anxiety disorders
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
US9359299B2 (en) 2011-04-04 2016-06-07 Georgetown University Small molecules for treating breast cancer
EP2771069A4 (en) 2011-10-27 2015-08-26 Mayo Foundation INHIBITION OF G-PROTEIN-COUPLED RECEPTOR-6-KINASE POLYPEPTIDE
CA2853806C (en) 2011-11-02 2020-07-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
JP2014533299A (ja) 2011-11-14 2014-12-11 シンタ ファーマシューティカルズ コーポレーション Ｂｒａｆ阻害剤とｈｓｐ９０阻害剤の組合せ療法
US9598395B2 (en) 2012-03-23 2017-03-21 The Regents Of The University Of California Premature-termination-codons readthrough compounds
US20150119250A1 (en) * 2012-04-05 2015-04-30 Howard University Methods for modulating plant response to environmentally-induced stress
US9340532B2 (en) 2012-12-14 2016-05-17 Phusis Therapeutics, Inc. Methods and compositions for inhibiting CNKSR1
CN103467398B (zh) * 2013-09-03 2015-01-21 浙江医药高等专科学校 三唑酰胺类化合物、其制备方法和其抗糖尿病用途
CN103554043B (zh) * 2013-09-03 2015-04-01 浙江医药高等专科学校 苯基取代的三唑酰胺类化合物及用途
CN103483282B (zh) * 2013-09-03 2015-04-22 浙江医药高等专科学校 苯基取代的三唑酰胺类化合物及用途
CN103467399B (zh) * 2013-09-03 2015-01-07 浙江医药高等专科学校 三唑酰胺类化合物、其制备方法和其用途
CN103483281B (zh) * 2013-09-03 2015-04-22 浙江医药高等专科学校 一类三唑酰胺类化合物、其制备方法和其抗糖尿病用途
WO2015164411A2 (en) * 2014-04-21 2015-10-29 Mayo Foundation For Medical Education And Research Small molecule inhibitors of g protein coupled receptor 6 kinases polypeptides
RU2626003C2 (ru) * 2014-04-28 2017-07-21 Общество с ограниченной ответственностью "Квантум Фармасьютикалс" Амид 1,2,4-триазол-3-илтиогликолевой кислоты, обладающий противовирусной активностью, или его фармацевтически приемлемые соли, фармацевтические композиции и их применение для лечения и профилактики гриппа
US10227356B2 (en) 2015-04-20 2019-03-12 Phusis Therapeutics, Inc. Compounds, compositions and methods for inhibiting CNKSR1
HRP20200690T1 (hr) 2015-05-20 2020-07-24 Amgen Inc. Agonisti triazola apj receptora
EP3380970B1 (en) 2015-11-24 2023-01-04 Sanford Burnham Prebys Medical Discovery Institute Novel azole derivatives as apelin receptor agonist
CN109311824A (zh) * 2016-03-10 2019-02-05 北京生命科学研究所 激酶抑制剂
WO2017165885A1 (en) * 2016-03-25 2017-09-28 Hemayet Ullah Methods for treating viral infection
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
WO2017197080A1 (en) * 2016-05-11 2017-11-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Modulators of p97 aaa atpase activity
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
US10675283B2 (en) 2017-03-24 2020-06-09 University Of South Florida Compositions and methods for white to beige adipogenesis
WO2018209083A1 (en) 2017-05-11 2018-11-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Modulators of p97 aaa atpase activity
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
WO2019200032A1 (en) 2018-04-11 2019-10-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 1,2,3-triazole inhibitors of p97 aaa atpase activity
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
US20220288033A1 (en) * 2019-09-04 2022-09-15 Agency For Science, Technology And Research Heterocyclic compounds as modulators of beta-catenin / tcf4 interaction
EP4075980B1 (en) * 2019-12-18 2025-07-23 Stinginn LLC Substituted 1,2, 4-triazoles and methods of use
CN112999221B (zh) * 2021-03-22 2022-04-12 苏州大学 一种三氮唑类化合物在制备抗肿瘤药物中的应用
US20230250089A1 (en) * 2022-02-09 2023-08-10 The Regents Of The University Of California Map4k3 small molecule drug inhibitors and methods of use thereof
US12180202B1 (en) 2023-10-16 2024-12-31 King Faisal University 2-[(1,3-benzothiazol-2-yl)imino]-5,5-diphenylimidazolidin-4-one as an antimicrobial compound
US11932612B1 (en) 2023-10-17 2024-03-19 King Faisal University 6-(5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)hexanoic acid as an antimicrobial compound
US12172970B1 (en) 2023-10-17 2024-12-24 King Faisal University 2-(5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)acetic acid as an antimicrobial compound
US11932610B1 (en) * 2023-10-17 2024-03-19 King Faisal University 4-(5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)butanoic acid as an antimicrobial compound
US11970465B1 (en) 2023-10-17 2024-04-30 King Faisal University Ethyl {[4-benzoyl-5-(3-fluorophenyl)-4H-1,2,4-triazol-3-yl]thio}acetate as an antimicrobial compound
US12054464B1 (en) 2023-10-23 2024-08-06 King Faisal University Methyl 4-((5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)methyl)benzoate as an antimicrobial compound
US11970466B1 (en) 2023-10-25 2024-04-30 King Faisal University 4-((5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)methyl)benzoic acid as an antimicrobial compound

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ198350A (en) * 1980-09-25 1985-02-28 Toyama Chemical Co Ltd Cephalosporins and intermediates;pharmaceutical compositions
DE3313721A1 (de) * 1983-04-15 1984-10-18 Agfa-Gevaert Ag, 5090 Leverkusen Farbfotografisches farbkupplerhaltiges aufzeichnungsmaterial
DE3439450A1 (de) * 1984-10-27 1986-05-07 Boehringer Ingelheim KG, 6507 Ingelheim 1,2,4-triazolo-carbamate und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel
US4826898A (en) * 1987-04-03 1989-05-02 Dainippon Ink And Chemicals, Inc. Colored polypropylene resin
WO1989006125A1 (en) * 1987-12-31 1989-07-13 Smithkline Beckman Corporation 4-aralkyl-5-substituted-1,2,4-triazole-5-thiols
US5498720A (en) * 1993-08-26 1996-03-12 Lee; An-Rong Certain triazole compounds and their pharmaceutical uses
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
IL166510A0 (en) * 2002-08-09 2006-01-15 Nps Pharma Inc 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5
JP2006518369A (ja) * 2003-02-21 2006-08-10 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 駆虫剤および殺虫剤組成物
EP1723123A4 (en) * 2004-03-08 2009-12-02 Wyeth Corp ION CHANNEL MODULATORS
US20080139560A1 (en) * 2004-03-08 2008-06-12 Scion Pharmaceuticals, Inc. Ion Channel Modulators

Also Published As

Publication number Publication date
WO2005097758A1 (en) 2005-10-20
BRPI0509172A (pt) 2007-08-28
JP2007530589A (ja) 2007-11-01
EP1730124A4 (en) 2009-04-01
EP1730124A1 (en) 2006-12-13
AU2005230867A1 (en) 2005-10-20
US20050288347A1 (en) 2005-12-29
CA2560954A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
MXPA06011046A (es) Ciertos compuestos basados en triazol, composiciones, y usos de los mismos.
TW200621253A (en) 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2007136592A3 (en) 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents
MY142777A (en) Substituted indole-o-glucosides
UA86042C2 (en) Substituted indazole-o-glucosides
TW200732349A (en) Anti-OX40L antibodies and methods using same
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
SG153800A1 (en) Pharmaceutical compositions
TNSN07196A1 (en) Potentiators of glutamate receptors
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
TW200728290A (en) Chemical compounds
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
WO2005087724A3 (en) Sulphonylpyrroles as hdac inhibitors
TW200718687A (en) Inhibitors of cytosolic phospholipase A2
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
MX2008001538A (es) Aril piridinas y metodos para su uso.
TW200738686A (en) Chemical compounds
EA200800357A1 (ru) Новые фармацевтические соединения

Legal Events

Date Code Title Description
FA Abandonment or withdrawal